Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Mukai, Hirofumi
Inoue, Kenichi
Rai, Yoshiaki
Ohno, Shinji
Ohtani, Shoichiro
Shimizu, Chikako
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Iwata, Hiroji
Toi, Masakazu
Funding for this research was provided by:
Pfizer
Article History
Received: 23 June 2020
Accepted: 11 September 2020
First Online: 21 October 2020
Compliance with ethical standards
:
: Y Rai has no conflicts of interest to report. N Masuda has received honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, Pfizer, and Takeda and research funding from AstraZeneca, Chugai, Eisai, Eli Lilly, Daiichi Sankyo, Kyowa-Kirin, MSD, Novartis, and Pfizer. H Mukai has received honoraria from AstraZeneca, Daiichi Sankyo, Pfizer, Taiho, and Takeda and research funding from the Japanese government, Daiichi Sankyo, Eisai, Nippon Kayaku, and Pfizer. K Inoue has received research funding from AstraZeneca, Chugai, Daiichi Sankyo, GlaxoSmithKline, Parexel, Puma Biotechnology, MSD, Novartis, and Pfizer. S Ohno has received honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, Kyowa Hakko Kirin, Novartis, Pfizer, and Taiho and research funding from Eisai and Taiho. S Ohtani has received honoraria from Chugai and Eisai. C Shimizu has received research funding from Eli Lilly. S Hashigaki is an employee of Pfizer R&D Japan. Y Muramatsu is an employee of Pfizer Japan Inc. Y Umeyama is an employee of Pfizer R&D Japan and stockholder in Pfizer. H Iwata has received honoraria and research funding from AstraZeneca and Pfizer and fees for promotional materials from AstraZeneca. M Toi has received honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, Genomic Health Institute, Kyowa-Hakko Kirin, MSD, Novartis, Pfizer, Taiho, and Takeda; research funding from AstraZeneca, Chugai, Eli Lilly, Novartis, Pfizer, and Taiho; served as a consultant/independent contractor for Kyowa-Hakko Kirin; and served on the advisory board for Genomic Health Institute.